Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.
BörsenkürzelHSDT
Name des UnternehmensHelius Medical Technologies Inc
IPO-datumJun 27, 2014
CEOMr. Dane C. Andreeff
Anzahl der mitarbeiter21
WertpapierartOrdinary Share
GeschäftsjahresendeJun 27
Addresse642 Newtown Yardley Road
StadtNEWTOWN
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl18940
Telefon12159446100
Websitehttps://heliusmedical.com/
BörsenkürzelHSDT
IPO-datumJun 27, 2014
CEOMr. Dane C. Andreeff
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten